Floatz logo

cd19/cd22-bispecific car-t cells

B-Cell Lymphoma Stage I

Beijing Tongren HospitalCell therapyPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the B-Cell Lymphoma Stage I cohort.

Asset / SponsorPhaseRating
Anti-Cd19 Anti-Cd20 Bispecific Car-T
Henan Cancer Hospital
Phase 1CC

Same molecule, other indications

cd19/cd22-bispecific car-t cells is also rated in:

B-Cell Lymphoblastic Leukemia/LymphomaDormant
B
Indicative ·
60 / 100
View asset →
Large B-Cell Lymphoma (LBCL)Dormant
CCC
Indicative ·
53 / 100
View asset →
B-cell non-Hodgkin lymphomaDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →